

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM774897

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Athyrium Opportunities III Acquisition LP		12/16/2022	Limited Partnership: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Societal CDMO, Inc. f/k/a Recro Pharma, Inc.		
<b>Street Address:</b>	1300 Gould Dr.		
<b>City:</b>	Gainseville		
<b>State/Country:</b>	GEORGIA		
<b>Postal Code:</b>	30504		
<b>Entity Type:</b>	Corporation: PENNSYLVANIA		
<b>PROPERTY NUMBERS Total: 8</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Serial Number:</b>	87687125	RECRO	
<b>Serial Number:</b>	86457241	INADEX	
<b>Registration Number:</b>	4777159	RECRO PHARMA	
<b>Serial Number:</b>	86457272	RELIXED	
<b>Serial Number:</b>	86861501	REXEVE	
<b>Serial Number:</b>	86861522	REXIEVE	
<b>Serial Number:</b>	86457244	XEDANX	
<b>Serial Number:</b>	86861551	XOLIV	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	404.885.2569		
<b>Email:</b>	nina.dhillon@troutman.com		
<b>Correspondent Name:</b>	Lauren N. Giambalvo		
<b>Address Line 1:</b>	600 Peachtree Street, NE, Suite 3000		
<b>Address Line 4:</b>	Atlanta, GEORGIA 30308		
<b>ATTORNEY DOCKET NUMBER:</b>	145963.17		
<b>NAME OF SUBMITTER:</b>	Nina Dhillon		

CH \$215.00 87687125

<b>SIGNATURE:</b>	/nina dhillon/
<b>DATE SIGNED:</b>	12/16/2022
<b>Total Attachments: 3</b> source=Release of Security Interest in Trademarks - Societal CDMO Inc fka Recro Pharma Inc_1 of 2 (Executed)#page1.tif source=Release of Security Interest in Trademarks - Societal CDMO Inc fka Recro Pharma Inc_1 of 2 (Executed)#page2.tif source=Release of Security Interest in Trademarks - Societal CDMO Inc fka Recro Pharma Inc_1 of 2 (Executed)#page3.tif	

## TERMINATION AND RELEASE OF SECURITY INTEREST IN TRADEMARKS

This TERMINATION AND RELEASE OF SECURITY INTEREST IN TRADEMARKS dated as of December 16, 2022 (this “Release”), is made by Athyrium Opportunities III Acquisition LP, a Delaware limited partnership, as Administrative Agent (the “Administrative Agent”), in favor of Societal CDMO, Inc. f/k/a Recro Pharma, Inc., a Pennsylvania corporation (“Company”).

**WHEREAS**, pursuant to that certain Security Agreement dated as of November 17, 2017 (as the same may be amended, modified, restated or supplemented from time to time, the “Security Agreement”), by and among the Company, the Administrative Agent for the Secured Parties referenced therein, and others party thereto, the Company granted to the Administrative Agent, for the benefit of the Secured Parties, a continuing security interest in, and continuing lien upon, any and all right, title and interest of Company’s Trademarks and trademark licenses, including those trademarks, trademark licenses and trademark applications set forth on Schedule 1 attached hereto (collectively, the “Trademark Collateral”); and

**WHEREAS**, pursuant to the Security Agreement, the Company executed and delivered to Administrative Agent the Notice of Grant of Security Interest in Trademarks dated as of November 17, 2017, which was recorded at the United States Patent and Trademark Office (“USPTO”) on November 17, 2017, at Reel 6209 Frame 0010, and correctively re-recorded at the USPTO on March 7, 2019, at Reel 6584 Frame 0724 (“Notice”).

**NOW THEREFORE**, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Administrative Agent and Company agree as follows:

**SECTION 1. Defined Terms.** All capitalized terms used herein but not otherwise defined herein have the meanings given to them in the Security Agreement or Notice.

**SECTION 2. Termination and Release.** Administrative Agent, on behalf of the Secured Parties, without any representation, warranty, recourse, or undertaking of any kind (whether express or implied), hereby:

(a) terminates, cancels, discharges, and releases the continuing security interest in, and continuing lien upon, any and all right, title and interest of Company’s Trademark Collateral, including those trademarks, trademark licenses and trademark applications set forth on Schedule 1 attached hereto, granted pursuant to the Security Agreement or Notice; and

(b) authorizes the recordation of this Release with the USPTO at Company’s expense.

**SECTION 3. Choice of Law.** This Release and obligations of the parties hereunder, and all of their successors, assigns, and transferees, shall be governed by and construed in accordance with the laws of the State of New York.


**IN WITNESS WHEREOF**, the Administrative Agent, on behalf of the Secured Parties, has caused this Release to be duly executed as of the date first set forth above.

ADMINISTRATIVE AGENT:

ATHYRIUM OPPORTUNITIES III ACQUISITION LP,  
a Delaware limited partnership, as Administrative Agent

By: ATHYRIUM OPPORTUNITIES  
ASSOCIATES III LP, its General Partner

By: ATHYRIUM OPPORTUNITIES  
ASSOCIATES III GP LLC, the General Partner  
of Athyrium Opportunities Associates III LP

By:   
Name: Rashida Adams  
Title: Authorized Signatory

Schedule 1

Societal CDMO, Inc. f/k/a Recro Pharma, Inc.  
(Pennsylvania corporation)

U.S. Trademarks

U.S. Trademarks owned by Societal CDMO, Inc. f/k/a Recro Pharma, Inc.

<u>Trademark</u>	<u>Registration Number / Application Number</u>	<u>Owner</u>
RECRO	87/687,125	Societal CDMO, Inc. f/k/a Recro Pharma, Inc.
INADEX	86/457,241	Societal CDMO, Inc. f/k/a Recro Pharma, Inc.
RECRO PHARMA	4777159 / 86/471,197	Societal CDMO, Inc. f/k/a Recro Pharma, Inc.
RELIXED	86/457,272	Societal CDMO, Inc. f/k/a Recro Pharma, Inc.
REXEVE	86/861,501	Societal CDMO, Inc. f/k/a Recro Pharma, Inc.
REXIEVE	86/861,522	Societal CDMO, Inc. f/k/a Recro Pharma, Inc.
XEDANX	86/457,244	Societal CDMO, Inc. f/k/a Recro Pharma, Inc.
XOLIV	86/861,551	Societal CDMO, Inc. f/k/a Recro Pharma, Inc.